NBM-BMX, A SPECIFIC HDAC 8 INHIBITOR, HAS BEEN QUALIFIED TO BE A NEW DRUG BY TAIWAN’S MINISTRY OF ECONOMIC AFFAIRS ALONG WITH THE COMPANY TO HAVE “BIOTECH NEW DRUG COMPANY” STATUS.

“NBM-BMX, a specific histone deacetylase 8 inhibitor, developed solely by NBM from scratch, has met the requirements by the “Biotech New Drug Industry Development Regulations” and other related provisions, to be recognized as an innovative new drug by Industrial Development Bureau, Ministry of Economic Affairs. With the endorsement, the company can get a number of tax-favored benefits.